Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes
Interventions
Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Healthy Volunteers
Interventions
Nabilone, CP-945,598, hyperglycemic clamp, euglycemic-hyperinsulinemic clamp
Other · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
GDM, Lactation
Interventions
Hyperinsulinemic-euglycemic clamp
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 2 Diabetes
Interventions
Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Type 2 Diabetes
Interventions
Glycemic clamping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Insulin Sensitivity
Interventions
Continuous Insulin administration during hyperinsulinemic euglycemic clamp test, Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers

The Role of the Omentum in the Treatment of Morbid Obesity

NCT00212160
Conditions
Obesity
Interventions
omentectomy
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Insulin Resistance
Interventions
VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Obesity
Interventions
human ghrelin, very low calorie diet, Hyperinsulinemic/Euglycemic Clamp
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
IGT - Impaired Glucose Tolerance, T2D
Interventions
Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response of Epinephrine

NCT02692313
Conditions
Diabetes Complications
Interventions
Epinephrine, Saline infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Type 1 Diabetes
Interventions
Clamp
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 23 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fatty Acid Oxidation Defects and Insulin Sensitivity

NCT02517307
Conditions
Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions
Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Completed No phase listed Observational Accepts healthy volunteers

Impact of Metabolic Flexibility on Changes in Metabolic Health

NCT06340321
Conditions
Obesity, Metabolic Syndrome
Interventions
Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber
Diagnostic Test · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protection Against Insulin Resistance in Obesity

NCT02717832
Conditions
Obesity, Insulin Resistance
Interventions
hyperinsulinemic-euglycemic clamp
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland